FDASIA Expedited Approval Provisions Offer Little Help To Ampligen
Executive Summary
Despite Hemispherx’s initial belief that the chronic fatigue syndrome drug might qualify under the FDA Safety and Innovation Act’s language encouraging increased use of accelerated approval, FDA officials suggest the pathway is not an option and the drug’s effect on an intermediate clinical endpoint has not been adequately demonstrated.
You may also be interested in...
FDA Uses AdComm Process To Shine Light On Ampligen’s Troubled Development
December’s Arthritis Advisory Committee review of Hemispherx’s drug provided FDA with the first public opportunity to explain in detail why the chronic fatigue syndrome drug, in development for almost 25 years, has not passed regulatory muster to date.
Chronic Fatigue Syndrome Drug Development Efforts Get A Boost From FDA
Agency is undertaking a series of activities with patients, advocacy groups and other stakeholders aimed at spurring development of new treatments. Hemispherx is hoping its investigational drug Ampligen, currently under FDA review, will become an early beneficiary of new statutory provisions on expedited approval.
Ampligen Chronic Fatigue Syndrome Data May Be Sufficient For FDA Approval
FDA is reviewing Hemispherx’s reanalysis of data from its Ampligen Phase III trial to determine if an additional confirmatory study is necessary.